Secondary analysis of 93 patients hospitalised with COVID-19 in the ACTIV-4a trial: higher plasma SARS-CoV-2 RNA was associated with 90-day death (HR 1.31) and thrombosis (HR 1.35); soluble thrombomodulin mediated an estimated 12.2% of the death link.
Secondary analysisn = 93
Zuchelkowski et al. Soluble Thrombomodulin Links Viremia and Mortality During COVID-19: Results From the ACTIV-4a Trial